TROPION-Breast01 (NCT05104866): This phase III trial is dedicated to evaluating the safety and effectiveness of DS-1062 in patients with inoperable or metastatic HR/HER2 breast cancer who have previously received one or two systems of chemotherapy [42]. This evidence concerns the gene ERBB2 and breast cancer.